Literature DB >> 17913657

Insights into JAK2-V617F mutation in CML.

Monica Bocchia, Alessandro M Vannucchi, Alessandro Gozzetti, Paola Guglielmelli, Giada Poli, Rosaria Crupi, Marzia Defina, Alberto Bosi, Lauria Francesco.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17913657     DOI： 10.1016/S1470-2045(07)70295-4

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  13 in total

1.  Simultaneous detection of JAK2 V617F mutation and Bcr-Abl translocation in a patient with chronic myelogenous leukemia.

Authors:  Monika Ribeiro Mello de Conchon; Juliana Lima Costa; Mafalda Megumi Yoshinaga Novaes; Pedro Enrique Dorlhiac-Llacer; Dalton de Alencar Fischer Chamone; Israel Bendit
Journal:  Int J Hematol       Date:  2008-07-16       Impact factor: 2.490

2.  Coexistence of JAK2V617F Mutation and BCR-ABL Translocation in a Pregnant Woman with Essential Thrombocythemia.

Authors:  You-Wen Qin; Yi-Ning Yang; Su Li; Chun Wang
Journal:  Indian J Hematol Blood Transfus       Date:  2014-04-11       Impact factor: 0.900

3.  Myeloproliferative neoplasms with concurrent BCR-ABL1 translocation and JAK2 V617F mutation: a multi-institutional study from the bone marrow pathology group.

Authors:  Craig R Soderquist; Mark D Ewalt; David R Czuchlewski; Julia T Geyer; Heesun J Rogers; Eric D Hsi; Sa A Wang; Carlos E Bueso-Ramos; Attilio Orazi; Daniel A Arber; Elizabeth O Hexner; Daria V Babushok; Adam Bagg
Journal:  Mod Pathol       Date:  2018-01-12       Impact factor: 7.842

4.  A man with concomitant polycythaemia vera and chronic myeloid leukemia: the dynamics of the two disorders.

Authors:  Ping Chong Bee; G G Gan; V S Nadarajan; N A Latiff; N Menaka
Journal:  Int J Hematol       Date:  2010-01-05       Impact factor: 2.490

5.  CBL, CBLB, TET2, ASXL1, and IDH1/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia.

Authors:  Hideki Makishima; Anna M Jankowska; Michael A McDevitt; Christine O'Keefe; Simon Dujardin; Heather Cazzolli; Bartlomiej Przychodzen; Courtney Prince; John Nicoll; Harish Siddaiah; Mohammed Shaik; Hadrian Szpurka; Eric Hsi; Anjali Advani; Ronald Paquette; Jaroslaw P Maciejewski
Journal:  Blood       Date:  2011-02-23       Impact factor: 25.476

6.  Impressive thrombocytosis evolving in a patient with a BCR-ABL positive CML in major molecular response during dasatinib treatment unmasks an additional JAK2V617F.

Authors:  Friederike Pastore; Stephanie Schneider; Oliver Christ; Wolfgang Hiddemann; Karsten Spiekermann
Journal:  Exp Hematol Oncol       Date:  2013-09-05

7.  Frequency of JAK2 V617F mutation in patients with Philadelphia positive Chronic Myeloid Leukemia in Pakistan.

Authors:  Najia Tabassum; Mohammed Saboor; Rubina Ghani; Moinuddin Moinuddin
Journal:  Pak J Med Sci       Date:  2014-01       Impact factor: 1.088

8.  Coexistence of JAK2 and BCR-ABL mutation in patient with myeloproliferative neoplasm.

Authors:  Abdulaziz Hassan; Livingstone Gayus Dogara; Ahmadu Aliyu Babadoko; Sani Awwalu; Aisha Indo Mamman
Journal:  Niger Med J       Date:  2015 Jan-Feb

9.  Concomitant JAK2 V617F-positive polycythemia vera and BCR-ABL-positive chronic myelogenous leukemia treated with ruxolitinib and dasatinib.

Authors:  A Zhou; E M Knoche; E K Engle; D A C Fisher; S T Oh
Journal:  Blood Cancer J       Date:  2015-10-02       Impact factor: 11.037

10.  Two cases of myeloproliferative neoplasm with a concurrent JAK2 (V617F) mutation and BCR/ABL translocation without chronic myelogenous leukemia phenotype acquisition during hydroxyurea treatment.

Authors:  Sang Hyuk Park; Hyun-Sook Chi; Young-Uk Cho; Seongsoo Jang; Chan-Jeoung Park; Dae-Young Kim; Je-Hwan Lee; Kyoo-Hyung Lee
Journal:  Ann Lab Med       Date:  2013-04-17       Impact factor: 3.464
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.